Asymchem on Bioeconhttps://en.bioecon.ru/companies/asymchem/Recent content in Asymchem on BioeconHugoen-USMon, 20 Jul 2026 13:49:10 +0700Chemoenzymatic API synthesis (biocatalytic small-molecule manufacturing)https://en.bioecon.ru/technology/chemoenzymatic-api-synthesis/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/chemoenzymatic-api-synthesis/Engineered-enzyme steps (transaminases, ketoreductases, lipases) substituted into small-molecule API routes to replace metal-catalysed or multi-step chemical sequences — anchored by Codexis’s CodeEvolver platform (the Merck sitagliptin transaminase case) in the US, Almac’s biocatalysis CDMO in the UK, Lonza’s HPAPI/biocatalysis toolkit in Switzerland, and Asymchem and WuXi AppTec’s biocatalysis-enabled CDMO platforms in China.Biosynthetic steroids (fermentation & biocatalytic API)https://en.bioecon.ru/technology/biosynthetic-steroids/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/biosynthetic-steroids/Corticosteroid and reproductive-hormone APIs made by mycobacterial fermentation of phytosterol into AD/ADD/9-OHAD precursors, then biocatalytic and semi-synthetic finishing — a globally-offshored manufacturing tier anchored by Olon, Farmabios and Gadea in Europe, Tianjin Tianyao in China, Symbiotec in India and Asymchem’s biocatalysis CDMO.